We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

136 hedge funds and large institutions have $409M invested in Aclaris Therapeutics in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more call options, than puts

Call options by funds: $2.57M | Put options by funds: $1.14M

106% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 16

62% more capital invested

Capital invested by funds: $252M → $409M (+$157M)

13.27% more ownership

Funds ownership: 77.29% → 90.56% (+13%)

11% more funds holding

Funds holding: 122 → 136 (+14)

3% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 40

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
136
Holders Change
+14
Holders Change %
+11.48%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
33
Increased
41
Reduced
40
Closed
16
Calls
$2.57M
Puts
$1.14M
Net Calls
+$1.43M
Net Calls Change
-$2.06M

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$31.5M
2
RCM
RA Capital Management
Massachusetts
+$23M
3
FLSM
Frazier Life Sciences Management
California
+$16.6M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$11.3M
5
KCM
Kalehua Capital Management
Texas
+$6.18M

Top Sellers

1
VC
Vivo Capital
California
-$7.5M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.03M
3
Morgan Stanley
Morgan Stanley
New York
-$2.26M
4
Renaissance Technologies
Renaissance Technologies
New York
-$2.1M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
51
Invesco
Georgia
$806K +$17K +5,032 +2%
Mackenzie Financial
52
Mackenzie Financial
Ontario, Canada
$800K +$720K +213,405 New
Bank of New York Mellon
53
Bank of New York Mellon
New York
$776K +$11.8K +3,507 +2%
UBS Group
54
UBS Group
Switzerland
$776K -$525K -155,724 -43%
VA
55
Verdad Advisers
Massachusetts
$739K +$665K +197,042 New
Qube Research & Technologies (QRT)
56
Qube Research & Technologies (QRT)
United Kingdom
$729K -$853K -252,665 -57%
EI
57
EAM Investors
California
$669K +$602K +178,378 New
Assenagon Asset Management
58
Assenagon Asset Management
Luxembourg
$665K +$76.7K +22,729 +15%
Fidelity Investments
59
Fidelity Investments
Massachusetts
$661K +$440K +130,546 +285%
T. Rowe Price Associates
60
T. Rowe Price Associates
Maryland
$588K +$55.9K +16,558 +12%
Creative Planning
61
Creative Planning
Kansas
$570K +$341K +100,917 +197%
ACM
62
ADAR1 Capital Management
Texas
$497K -$1.62M -481,560 -78%
American Century Companies
63
American Century Companies
Missouri
$445K +$139K +41,134 +53%
N
64
Nuveen
North Carolina
$443K -$404K -119,810 -50%
AA
65
ALPS Advisors
Colorado
$368K +$31.1K +9,209 +10%
XT
66
XTX Topco
Cayman Islands
$367K -$51.1K -15,138 -13%
Bank of America
67
Bank of America
North Carolina
$298K +$50.7K +15,018 +23%
RhumbLine Advisers
68
RhumbLine Advisers
Massachusetts
$283K +$12.1K +3,597 +5%
QC
69
Quadrature Capital
United Kingdom
$272K +$50.2K +14,870 +26%
AQR Capital Management
70
AQR Capital Management
Connecticut
$272K -$106K -31,384 -30%
VGA
71
Vanguard Global Advisers
Pennsylvania
$258K +$232K +68,793 New
CP
72
CenterBook Partners
Connecticut
$250K +$225K +66,598 New
MIM
73
MetLife Investment Management
New Jersey
$165K +$61.7K +18,273 +71%
Mirae Asset Global ETFs Holdings
74
Mirae Asset Global ETFs Holdings
Hong Kong
$163K +$3.44K +1,021 +2%
Cambridge Investment Research Advisors
75
Cambridge Investment Research Advisors
Iowa
$157K – – –
1 2
3
4 5

ACRS Hedge Fund Activity: Q1 2026 in Review

136 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2026, worth a combined $409M — up 62% from $252M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ACRS positions and 16 closed out — a net gain of 17 holders — while 41 added to existing stakes and 40 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $31.5M. The largest seller was Vivo Capital, cutting an estimated $7.5M.

  • 136 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2026, up from 122 in Q4 2025.
  • Funds reported $409M of Aclaris Therapeutics stock for Q1 2026, up 62% quarter-over-quarter.
  • 33 funds opened new Aclaris Therapeutics positions in Q1 2026 and 16 closed out, a net change of +17 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2026 was Deep Track Capital, an estimated $31.5M added.
  • The largest Aclaris Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $7.5M sold.

Based on aggregated 13F filings for Q1 2026.